左西孟旦联合曲美他嗪治疗肺动脉高压患者的疗效及对心肌型脂肪酸结合蛋白表达的影响

目的 探讨左西孟旦联合曲美他嗪治疗肺动脉高压（PH）患者的疗效对心肌型脂肪酸结合蛋白（H-FABP）表达的影响。方法 采用回顾性、总结研究方法，选择2016年1月-2018年2月在漯河市中医院诊治的PH患者101例作为研究对象，根据治疗方法的不同分为观察组51例与对照组50例，对照组给予曲美他嗪治疗，观察组给予左西孟旦联合曲美他嗪治疗，两组都治疗观察1个月。比较两组临床疗效、心功能指标改善情况、肺动脉收缩压（PASP）及H-FABP变化情况。结果 治疗后观察组的总有效率为92.2%，对照组为72.0%，观察组显著优于对照组（P<0.05）。治疗后，观察组患者左室收缩末径（LVSD）、左室舒张末径（LVDD）、左室射血分数（LVEF）指标均明显改善，差异有统计学意义（P<0.05）；对照组患者治疗后LVEF、LVSD指标明显改善，差异有统计学意义（P<0.05）；治疗后，观察组LVDD明显高于对照组，差异有统计学意义（P<0.05）。治疗后两组患者PASP均低于治疗前，同组治疗前后比较差异有统计学意义（P<0.05）；观察组也低于对照组，差异具有统计学意义（P<0.05）。治疗后，两组患者血清H-FABP水平均明显低于治疗前，同组治疗前后比较差异有统计学意义（P<0.05）；观察组明显低于对照组，差异具有统计学意义（P<0.05）。结论 左西孟旦联合曲美他嗪治疗PH能抑制H-FABP的释放，降低PASP，促进改善心功能，从而提高治疗效果。

Effect of levosimendan combined with trimetazidine on expression of cardiac fatty acid binding protein in patients with pulmonary hypertension

Objective To investigate the effects of levosimendan combined with trimetazidine on the expression of cardiac fatty acid binding protein (H-FABP) in patients with pulmonary hypertension (PH).Methods From January 2016 to February 2018,101 cases of PH patients treated in our hospital were selected and were divided into the 51 cases of experimental group and 50 cases of control group accorded to the different treatment methods.The control group were treated with trimetazidine,and the experimental group were given levosimendan combined with trimetazidine treatment.The changes of H-FABP were recorded.Results After treatment,the total effective rate of the experimental group were 92.2%,while that of the control group were 72%,the experimental group were better than the control group (P<0.05).After treatment,the LVEF,LVDD and LVSD in the experimental group compared before treatment were statistically significant (P<0.05),the comparison of LVEF and LVSD in the control group were statistically significant before and after treatment (P<0.05),and the difference of LVDD compared between the two groups after treatment were statistically significantly (P<0.05).After treatment,the systolic blood pressure (PASP) of the experimental group and the control group were lower than that before treatment (P<0.05),and the experimental group were also lower than that of the control group (P<0.05).After treatment,the serum H-FABP of the experimental group and the control group were lower than that before treatment (P<0.05),and the experimental group were lower than that of the control group (P<0.05).Conclusion Levosimendan combined with trimetazidine in the treatment of PH can inhibit the release of H-FABP,reduce PASP,and improve cardiac function,thereby improve the therapeutic effect.